<DOC>
	<DOCNO>NCT02681172</DOCNO>
	<brief_summary>This phase 4 study explore , context present French clinical practice , impact florbetaben 18F ( FBB ) patient evaluate AD require biomarker etiologic determination cognitive functional impairment , : 1. lumbar puncture feasible medical condition 2. result cerebrospinal fluid ( CSF ) analysis consider ambiguous treat physician 3. lumbar puncture refuse patient</brief_summary>
	<brief_title>Impact FBB PET Amyloid Imaging Change Diagnosis Patients With AD</brief_title>
	<detailed_description>It conduct outpatient set tertiary memory clinic ( CMRR ) France patient preliminary diagnosis base completion prior , full diagnostic workup , 12 month previously - could include , limited brain imaging need ( magnetic resonance imaging ( MRI ) compute tomography ( CT ) ) , neuropsychological evaluation include Mini-Mental Status Examination ( MMSE ) , CSF examination examination accord `` Haute Autorité de santé '' ( HAS , National Authority Health , France ) Recommendations - : 1. lumbar puncture feasible medical condition 2. result cerebrospinal fluid ( CSF ) analysis consider ambiguous treat physician 3. lumbar puncture refuse patient For subject study comprise 3 outpatient clinic visit record information previous work ups perform FBB Positron Emission Tomography ( PET ) scan ( Visit 1 : screening/ baseline , Visit 2 : PET scan , Visit 3 : subject inform FBB PET scan result ) . At Visit 1 , initial diagnosis base previous work collect rat five-point Likert confidence scale Physician . At Visit 2 , FBB PET scan perform . Adverse event report exam 7 day PET procedure . At Visit 3 , base amyloid PET scan result , change diagnosis collect , addition physician confidence .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients evaluate Alzheimer disease relate dementias accord HAS recommendation ( atypical dementia , early onset rapid progressive dementia ) Patients previously evaluate AD related dementia CSF examination recommend last 12 month , lumbar puncture contraindicate refuse CSF result ambiguous , Patients currently evaluate AD related dementia CSF examination recommend lumbar puncture contraindicate refuse Patients study partner willing able accompany him/her clinic visit duration protocol Patients able complete clinical visit accord protocol Patients able tolerate 20minute FBB PET scan Patient legal representative provide inform consent study participation , visit data source verification . The subject previous beta amyloid image scan Any significant systemic illness unstable medical condition could lead difficulty comply protocol Is currently receive investigational pharmaceutical product participate clinical trial investigational pharmaceutical product within 30 day prior screen and/or administer radiopharmaceutical within 10 radioactive halflives prior study drug administration study For female childbearing age , positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CSF</keyword>
	<keyword>Alzheimer 's Disease ( AD ) relate dementia</keyword>
	<keyword>HAS recommendation</keyword>
</DOC>